Found 600 clinical trials
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if
- 49 views
- 05 Feb, 2021
- 4 locations
Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP
This study is to be performed as an open label, multicenter, single arm study of 2X-121 to evaluate anti-tumor efficacy of 2X-121 as single agent therapy in a 28-days cycle in advanced ovarian
- 0 views
- 01 Aug, 2021
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
At present, the standard treatment for platinum-resistant ovarian cancer patients is platinum-free chemotherapy, with poor efficacy and tolerance. The combination of anti-angiogenic drugs and
- 0 views
- 27 Jan, 2021
- 1 location
The IPLA-OVCA Trial Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
Surgery and chemotherapy combined constitute first line treatment in women with advanced ovarian cancer. The aim of surgery apart from staging is cytoreduction, i.e. surgical resection of tumour
- 0 views
- 30 Jan, 2021
- 1 location
Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer
The aim of this study is to explore the effectiveness and safety of camrelizumab combined with apatinib mesylate in the treatment of relapsed platinum-resistant epithelial ovarian cancer
- 0 views
- 25 Jan, 2021
- 1 location
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
-resistant recurrent ovarian cancer.
- 0 views
- 28 Jan, 2021
- 1 location
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
-Refractory Relapsed Ovarian Cancer.
- 0 views
- 12 Jun, 2021
- 7 locations
Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
This is a Phase 3 study of AVB-S6-500 in combination with paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. This is a randomized, double-blind, placebo-controlled
- 0 views
- 04 Jul, 2021
- 28 locations
Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer
participants with high-grade serous ovarian cancer (HGSOC, including fallopian tube and primary peritoneal cancer). This study has an umbrella design. The trial consists of dose escalation (DES) and expansion
- 0 views
- 05 Jul, 2021
- 1 location
Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer
epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer, regardless of platinum sensitivity. Population studied will be female participants experiencing a 1st, 2nd, or 3rd
- 113 views
- 25 Jan, 2021
- 3 locations